.jpg)
The Medicines Company released its financial statement for the second quarter of 2017 on Aug. 9 and let the public know how its business and its clinics are going so far through 2017.
Through its second-quarter activities, The Medicines Company said it a release it likes the outcomes it saw in TANGO-2 testing of meropenem-vaborbactam, which is being tested on how it works in helping people fight carbapenem-resistant Enterobacteriaceae (CRE) afflictions in the blood, urinary tract, lung and abdomen. Those outcomes so far reflect that meropenem-vaborbactam does better than the strongest treatment now on the market in fighting those conditions.
The Medicines Company said it is also planning Phase III testing for inclisiran to measure how inclisiran does in cutting down LDL cholesterol.
